Detection of multiple druggable mutations of lung cancer from cytology specimens by MINtS: An advanced medicine A trial

MINtS 从细胞学标本中检测肺癌的多种可用药突变:一项先进的医学试验

阅读:6
作者:Kazutaka Fujita, Ryo Arai, Satoshi Shoji, Ryota Saito, Motoko Nomura, Takamasa Hotta, Hajime Asahina, Masanori Kawakami, Ichiro Nakachi, Yukihiro Hasegawa, Kohei Okafuji, Aya Suzuki, Akihiko Miyanaga, Noriaki Sunaga, Hiromi Nagashima, Naoya Ikeda, Satoshi Watanabe, Yoshiaki Nagai, Megumi Furuta, Hid

Abstract

Most multigene mutation tests require tissue specimens. However, cytological specimens are easily obtained in the clinical practice and provide high-quality DNA and RNA. We aimed to establish a test that utilizes cytological specimens and performed a multi-institutional study to investigate the performance of MINtS, a test based on next-generation sequencing. A standard procedure for specimen isolation was defined. The specimens were considered suitable for the test if >100 ng DNA and >50 ng RNA could be extracted from them. In total, 500 specimens from 19 institutions were investigated. MINtS detected druggable mutations in 63% (136 of 222) of adenocarcinomas. Discordant results between MINtS and the companion diagnostics were observed in 14 of 310 specimens for the EGFR gene, and 6 of 339 specimens for the ALK fusion genes. Confirmation by other companion diagnostics for the EGFR mutations or the clinical response to an ALK inhibitor all supported the results obtained by MINtS. MINtS along with the isolation procedure presented in the current study will be a platform to establish multigene mutation tests that utilize cytological specimens. UMIN000040415.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。